SCHEMBL21807256

SCHEMBL21807256

CCOC(=O)C(=O)c1ccc(F)c2c1CN(Cc1ccccc1)C2

nearest known ligand 0.45

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 6/20 0.45
KMT2A Q03164 6/20 0.45
ALDH1A1 P00352 4/20 0.41
LMNA P02545 3/20 0.41
MAPT P10636 3/20 0.41
ADORA1 P30542 1/20 0.41
GAA P10253 1/20 0.41
HPGD P15428 1/20 0.39
CASP3 P42574 1/20 0.39
CYP3A4 P08684 1/20 0.39
CYP2D6 P10635 1/20 0.39
CYP2C9 P11712 1/20 0.39
CYP2C19 P33261 1/20 0.39
TSHR P16473 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
POLB P06746 2/20 0.39
KDM4E B2RXH2 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21807680 0.84 ALDH1A1 (0.43) MEN1KMT2AALDH1A1TSHRSMN1; SMN2
SCHEMBL15060454 0.72 KMT2A (0.43) MEN1KMT2AALDH1A1LMNAMAPT
SCHEMBL31158622 0.71 SIGMAR1 (0.44) ALDH1A1LMNA
SCHEMBL21522001 0.71 SIGMAR1 (0.44) ALDH1A1LMNA
SCHEMBL21522072 0.71 KMT2A (0.47) MEN1KMT2AALDH1A1LMNAMAPT
SCHEMBL15056562 0.71 PTGDR2 (0.63)
SCHEMBL6057578 0.70 CNR1 (0.47) MEN1KMT2AALDH1A1LMNAMAPT
SCHEMBL2498608 0.69 CES2 (0.59) MEN1KMT2AALDH1A1LMNAMAPT
SCHEMBL4525709 0.69 SIGMAR1 (0.44) ALDH1A1LMNAGAACYP2C19KDM4E
SCHEMBL29785626 0.68 MEN1 (0.62) MEN1KMT2AALDH1A1LMNAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230065368-A1 INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 9X FORMA THERAPEUTICS, INC. 2023-03-02 US disclosed
US-20230065368-A1 INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 9X FORMA THERAPEUTICS, INC. 2023-03-02 US disclosed
EP-3852790-A1 INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 9X Forma Therapeutics, Inc. (US) 2021-07-28 EP disclosed
CN-113164571-A Inhibition of ubiquitin-specific peptidase 9X 福马治疗股份有限公司 2021-07-23 CN disclosed
WO-2020061261-A1 INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 9X FORMA THERAPEUTICS, INC. (US) 2020-03-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230065368-A1 INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 9X USP9X, USP19, USP39 MEN1 3166/4885KMT2A 1040/4885ALDH1A1 1794/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.